Skip to content

Impact of Passive Heat on Metabolic, Inflammatory and Vascular Health in Persons With Spinal Cord Injury

Passive Heating as an Accessible and Tolerable Strategy to Improve the Inflammatory Profile and Cardiometabolic Health in People With Spinal Cord Injury

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04971408
Acronym
SCIPHS
Enrollment
10
Registered
2021-07-21
Start date
2022-07-01
Completion date
2024-06-30
Last updated
2026-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injury, Chronic Inflammation, Glucose Metabolism, Endothelial Function

Keywords

spinal cord injury

Brief summary

SCI results in higher incidence of heart disease and diabetes and heart disease is the most common cause of death. Chronic inflammation, deleterious changes in vascular structure and impaired glucose metabolism are risk factors that contribute to both heart disease and diabetes. While exercise can help reduce these risk factors, paralysis and impaired accessibility often precludes exercise in persons with SCI. New research in able-bodied persons demonstrates passive heating decreases inflammation and improves vascular function. Similar studies in persons with SCI suggest they may also have the same health benefits however these studies only investigated the impact of short term (one episode) passive heating (as opposed to repeated bouts). Repeated bouts of heat exposure will likely be required to impact chronic inflammation, but this has never been tested in persons with SCI. This study will test the impact of repeated bouts (3x/week) of passive heat stress over a longer term (8 weeks) on inflammation, metabolism and vascular function.

Interventions

After arm 1, passive heat stress 3x/week x8 weeks.

OTHERControl

participant engage in activity as usual

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

passive heat stress with water perfused heat suits and electrical heating blankets

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Stable SCI over 1 year of duration

Exclusion criteria

* Persons who smoke cigarettes * Daily administration of anti-inflammatory medications * Daily administration of vasoactive medications * Pressure ulcer stage 3 or 4 * History of heat related illness

Design outcomes

Primary

MeasureTime frameDescription
Interleukin-6change from 0 weeks to 8 weeks to 16 weeksPlasma concentration, which was determined using enzyme-linked immunosorbent assays.

Secondary

MeasureTime frameDescription
Maximal Cutaneous Vascular Conductancechange from 0 weeks to 8 weeks to 16 weeksCutaneous vascular conductance (CVC) in response to local heating measured via laser doppler flowmetry. Following heating of the skin for 10 min at a temperature of 34C, the skin was locally heated to 45C, which was maintained for at least 30 min (maximal CVC). The values in the data table reflect the percentage of maximum conductance of the skin at 34 degrees Celsius, when the skin is heated to 45 degrees Celsius at each time point (i.e., baseline, after control, and after intervention).
Glucose Tolerancechange from 0 to 8 to 16 weeksglucose AUC from 3h oral glucose tolerance test
TNF-alphachange from 0 to 8 to 16 weeksplasma concentration
Interleukin-1rachange from 0 to 8 to 16 weeksplasma concentration

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMichelle B Trbovich, MD

South Texas Health Care System, San Antonio, TX

Participant flow

Pre-assignment details

Each enrolled participant completed a time-control phase of 8 weeks prior to the passive heating intervention.

Baseline characteristics

Characteristic
Age, Continuous45 years
STANDARD_DEVIATION 14
BMI in kg/m228.0 kg/m2
STANDARD_DEVIATION 3
Race/Ethnicity, Customized
Black
2 Participants
Race/Ethnicity, Customized
Hispanic
4 Participants
Race/Ethnicity, Customized
White
4 Participants
Sex: Female, Male
Female
2 Participants
Sex: Female, Male
Male
8 Participants
Years since injury9.2 years
STANDARD_DEVIATION 10.5

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 10
other
Total, other adverse events
0 / 101 / 10
serious
Total, serious adverse events
0 / 100 / 10

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026